APPLICATION OF NKG2D INHIBITORS FOR TREATMENT OF CARDIOVASCULAR AND METABOLIC DISEASES, SUCH AS DIABETES TYPE 2

摘要

1. The use of a therapeutically effective amount of an agent that inhibits the activation or signaling of NKG2D in a subject for the treatment of type 2 diabetes. The use of a therapeutically effective amount of an agent that blocks NKG2D ligand binding interaction in a subject for the treatment of type 2 diabetes. 3. The use of a therapeutically effective amount of an agent inhibiting NKG2D activation or signaling in a subject for treating a pathological condition that can be regulated or normalized by inhibiting NKG2D, wherein the pathological condition is selected from the group consisting of type 2 diabetes, cardiovascular disease, inflammatory diseases and diseases associated with metabolic dysfunction. 4. The use of a therapeutically effective amount of an agent that blocks the NKG2D ligand binding interaction in a subject for treating a pathological condition that can be regulated or normalized by inhibiting NKG2D, wherein the pathological condition is selected from the group consisting of type 2 diabetes, cardiovascular disease, inflammatory diseases and diseases associated with metabolic dysfunction. 5. The use according to any one of claims 1 to 4, in which the subject is a human. The use according to any one of claims 1 to 4, wherein the agent is selected from the group consisting of soluble NKG2D, an antibody or an antigen binding fragment thereof specifically binding to NKG2D, a NKG2D ligand, and an inhibitor of the activity or expression of the NKG2D ligand. The use of claim 6, wherein the agent is an antibody or antigen binding fragment thereof specifically binding